Owing to its availability, ease of collection and correlation with (patho-) physiology, urine is an attractive source for clinical proteomics. However, the lack of comparable datasets from large cohorts has greatly hindered development in this field. Here we report the establishment of a high resolution proteome database of naturally occurring human urinary peptides and proteins -ranging from 800-17,000 Da -from over 3,600 individual samples using capillary electrophoresis coupled to mass spectrometry, yielding an average of 1,500 peptides per sample. All processed data were deposited in an SQL database, currently containing 5,010 relevant unique urinary peptides that serve as classifiers for diagnosis and monitoring of diseases, including kidney and vascular diseases. Of these, 352 have been sequenced to date. To demonstrate the applicability of this database, two examples of disease diagnosis were provided: For renal damage diagnosis, patients with a specific renal disease were identified with high specificity and sensitivity in a blinded cohort of 131 individuals. We further show definition of biomarkers specific for immunosuppression and complications after transplantation (Kaposi's sarcoma). Due to its high information content, this database will be a powerful tool for the validation of biomarkers for both renal and nonrenal diseases.
SUMMARY
Owing to its availability, ease of collection and correlation with (patho-) physiology, urine is an attractive source for clinical proteomics. However, the lack of comparable datasets from large cohorts has greatly hindered development in this field. Here we report the establishment of a high resolution proteome database of naturally occurring human urinary peptides and proteins -ranging from 800-17,000 Da -from over 3,600 individual samples using capillary electrophoresis coupled to mass spectrometry, yielding an average of 1,500 peptides per sample. All processed data were deposited in an SQL database, currently containing 5,010 relevant unique urinary peptides that serve as classifiers for diagnosis and monitoring of diseases, including kidney and vascular diseases. Of these, 352 have been sequenced to date. To demonstrate the applicability of this database, two examples of disease diagnosis were provided: For renal damage diagnosis, patients with a specific renal disease were identified with high specificity and sensitivity in a blinded cohort of 131 individuals. We further show definition of biomarkers specific for immunosuppression and complications after transplantation (Kaposi's sarcoma). Due to its high information content, this database will be a powerful tool for the validation of biomarkers for both renal and nonrenal diseases.
INTRODUCTION
Analysis of urine plays a central role in clinical diagnostics. The human urinary proteome/peptidome has been extensively investigated to gain information on disease processes affecting the kidney and the urogenital tract [1] [2] [3] . Urinary proteins and peptides originate not only from glomerular filtration, but also from tubular secretion, epithelial cells shed from the kidney and urinary tract, secreted exosomes, and semen [4] [5] [6] . Thus, in principle, urine is a rich source of biomarkers for a wide range of diseases due to specific changes in its proteome/peptidome [7] [8] [9] [10] . To test the feasibility of urinary proteomics as a non-invasive diagnostic tool, large-scale studies are needed to analyze urine with reliable and quantitative methods. A variety of techniques have been applied to this effort, including two-dimensional electrophoresis combined with mass spectrometric and/or immunochemical identification of proteins [11] [12] [13] , liquid chromatography coupled to mass spectrometry (LC-MS) 14, 15 , and surface-enhanced laser desorption ionization mass spectrometry (SELDI-MS) 16 .
Due mostly to technical challenges, studies of urine based on proteomic methods often included only two groups of subjects (i.e., healthy controls versus patients with one disorder), and low numbers of patients and lack of comparability severely limit the suitability of such data for a meta-analysis to define biomarkers. Consequently, the findings from several studies cannot be combined to construct a broad database. Ideally, the analysis must be accomplished within a reasonably short time with high resolution, enabling profiling of an adequate number of features from sufficient samples to yield robust diagnostic panels.
Capillary electrophoresis coupled to mass spectrometry (CE-MS) enables reproducible and robust high-resolution analysis of several thousand low-molecular-weight urinary proteins/peptides in less than an hour 1 . This approach has been used to analyze urine samples from healthy volunteers and patients with various diseases [17] [18] [19] [20] [21] [22] [23] [24] . The high number of datasets analyzed using identical conditions on the same instruments allows the establishment of a low-molecular-weight proteome database that can serve as a basis for the diagnosis, classification, and monitoring of a wide range of diseases using proteome analysis. Here, we report on the establishment of a database of urinary peptides analyzed by CE-MS and illustrate the application of this database to chronic renal diseases (CRD) and to non-renal diseases.
RESULTS
All urine samples were prepared identically and analyzed by CE-MS analysis, using identical instruments. Analysis resulted in individual data sets containing information on generally 1,200-2,000 peptides and proteins per sample. All information recommended by the "minimum information about proteomics experiments" (MIAPE) guidelines 25 about proteome analysis using CE and MS is recorded, and available upon request. The data were evaluated using MosaiquesVisu
26
(see methods), resulting in a list of peptides/proteins defined by mass, migration time, and ion-counts, serving as a measure of relative abundance. Different charge states of identical peptides/proteins were combined and included as a single identification in the database. A list of tentatively identified peptides of any sample is obtained and subsequently calibrated using "internal standards", peptides generally present in urine 21 (see methods). This allows the digital compilation of individual datasets into a specific "disease group" that can be compared to any desired "control group", enabling the identification of statistically significant changes that result in the definition of potential biomarkers. Only datasets that fulfilled all quality control criteria (see methods) were subsequently utilized and included in the database, which currently includes CE-MS data from 28 different pre-selected pathophysiological conditions (see figure 1) .
To improve the mass accuracy, several samples were analyzed using CE-online coupled to Fourier transform-ion cyclotron resonance mass spectrometry (FT-ICR-MS).
Due to the high cost and the lower sensitivity of the FT-ICR MS instrument used in comparison to TOF-instruments, it was not practical to analyze all samples using CE-FT-ICR MS, and only a set of 20 samples was re-analyzed using this technique. Owing to the higher detection limit of the FT-ICR instrument (in comparison to the ESI-TOF used), the number of FT-ICR-traceable peptides was significantly lower (a factor of~10). However, the analysis using CE-FT-ICR resulted in the definition of over 300 urinary peptides, and 80 of these precise masses (mass deviations <0.5 ppm) were utilized to calibrate the TOF-MS derived masses. The high FT-ICR MS resolution also enabled an accurate analysis of the first isotope signal of ions with z>6, which is crucial for the exact mass determination of proteins and high molecular weight peptides. These data were used to refine the TOF-MS masses in the human urinary proteome database. Consequently, 'FT-ICR-calibrated' TOF masses of most peptides revealed a deviation from the theoretical mass of 3±9 ppm.
All detected peptides and proteins in the 3,687 human urine samples that passed all quality control criteria (on average, 1,724 peptides/proteins were detected in each individual urine sample, ranging from 983 to 4,094) were deposited in a Microsoft SQL database and subsequently matched for further analysis and comparison of individual samples. This process resulted in the definition of 116,869 different peptides and proteins.
Each peptide was assigned a unique identification number (Protein ID). As described previously 22, 27 , several of these peptides appeared sporadically, being observed in only one or a few samples. 
Application of the human urinary proteome database
The main purpose of this database is to serve as a universal platform for identification and validation of biomarkers for a variety of diseases/pathophysiological changes. This process is demonstrated in the following two examples:
Renal Disease
For the selection of disease-specific biomarkers, the data from individual samples were compiled as described previously 17, 21 and grouped according to the patients' profiles (diagnostic group). These were healthy subjects (N=386) and patients with various biopsyproven renal diseases (N=226) (for details, see These biomarkers were again combined in an SVM-based model. Upon complete crossvalidation, the models enabled correct classification of the FSGS patients with 100% sensitivity and 95.5% specificity, and the MNGN patients with 100% sensitivity and 90.3% 
Non-renal Disease
An example for the application of the urinary database to non-genitourinary diseases is the identification and validation of biomarkers indicating immunosuppression in organ or stem cell transplantation. In a reference cohort of 395 urine samples (135 patients on immunosupression and 260 controls, see 
DISCUSSION
Here we report on the establishment of a database of naturally occurring urinary peptides and proteins and demonstrate its application to the definition of biomarkers of human diseases. These biomarkers apparently reflect primary pathogenetic changes as well as the reaction to the disease. Hence, their usefulness extends beyond the applicability to diseases of the urogenital tract, and the approach may be universally applicable to diseases that result in systemic changes. While genetic analysis can predict the risk of a disease, proteomics, with its potential to monitor dynamic processes, may more clearly show at which point the risk manifests itself as disease and also facilitate monitoring of the response to therapy. Thus, these methods are complementary in personalized medicine 32 .
Recently, several groups reported on the sequencing of an array of urinary proteins 12, 33 .
While these data impressively demonstrate the large amount of proteinspotential information -contained in urine, critical or even mandatory information for their application in the definition of biomarkers is missing:
All reports are on tryptic digests of urinary proteins, and the sequences obtained from the tryptic peptides allow the authors to tentatively assign a protein to this sequence with variable confidence. Unfortunately, due to the in vitro manipulation of samples via digestion, it is not possible to define which species are actually present in the urine at the time of sampling. The actually occurring protein(s) will generally not be the protein in the database (e.g. Albumin precursor), but one or several variably post-translationally modified (PTM) proteins. In fact, PTMs are often the hallmark of the potential biomarker, e.g.
advanced glycation endproducts as markers for uremia 34 . The information that is required is the definition of the peptide/protein present in urine. Further, if biomarkers are to be defined, information on the relative abundance of proteins/peptides is mandatory.
We have therefore attempted to obtain such critical information: the naturally occurring protein/peptide is defined by mass and migration time, and the relative abundance is defined on ion-counting, set in relation to "internal standards", mostly specific collagen fragments that are present in almost every sample and appear not to change significantly in all the samples and disease-groups investigated to date. While this approach does not initially allow identification via sequence, it does allow for tentative identification based on mass and migration time. Sequencing was performed in a second step, but does meet several obstacles associated with sequencing of naturally occurring peptides [tryptic digests cannot be utilized, as these would result in a loss of connectivity to the original identification parameters 35 ]. Major obstacles are the frequently occurring PTMs that change the mass, which then is different from the theoretical mass present in the database, and the higher degree of freedom, as not pre-set terminal Arginine or Lysine can be employed in the database search. Further, search algorithms are generally adapted to the needs of tryptic digests, which differ greatly from the requirements for de novo sequencing of naturally occurring peptides or proteins (see also e.g. 1, 27 ).
CE-MS analysis of urine enables tentative identification of biomarkers for a variety of diseases of the kidney and the urogenital tract 17-19, 21, 22, 36 , although the high biological variability of peptides/proteins presents a serious methodological impediment. Therefore, it appears imperative to evaluate clinical conditions not on the basis of single peptide/protein markers, but rather on the basis of a panel of biomarkers that must be derived from distinct and clearly defined molecules. A panel of biomarkers will tolerate changes in individual analytes without jeopardizing the diagnostic precision, i.e. such variability will not result in gross changes of the diagnostic result.
While the exact sequences of biomarkers are not required to exploit their diagnostic potential, the sequences may offer further insight into the pathogenesis of a disease, (patho-) physiological mechanisms, and design of relevant therapeutics. Hence, sequence analysis of naturally occurring peptides in urine completes the content of this database.
Most of the original proteins have also been identified by other research groups 12, 33 , but the majority of naturally occurring peptides have not been defined. This is also reflected by the finding that collagen fragments represented the most abundant peptides in urine (see table 1 ).
Most of these naturally occurring urinary peptides are the result of proteolytic activity. Extracellular proteases may reflect the presence of the disease and its progression 37 . Complex changes in protease activities may be more readily recognized by the pattern of proteolytic fragments generated than by direct assessment of the specific protease activity 38 . CE-MS analysis may be suitable to display the regulated activity of proteases and protease inhibitors by displaying potential products and enabling monitoring of their concentrations.
To assess the value of the urinary proteome database, we utilized the data for the diagnosis of CRD as a representative example for diseases that are related to direct involvement of the urogenital tract. Using this database, biomarkers could be defined that allowed classification of a blinded cohort of urine samples, which distinguished 35 healthy controls from 96 patients with CRD (sensitivity 89.6%, specificity 94.3%) (ROC analysis is shown in figure 3B ). The potential of the approach was further underlined by the assessment of the same dataset using multiple panels. Without any additional measurements, the 131 subjects were reassessed using two additional disease-specific As we learn to better appreciate the huge individual differences in the responses of patients to therapy, objective methods to measure treatment responses will become of prime importance so as to tailor the therapy to the individual. Noninvasive urinary proteomics has an advantage in that such monitoring is possible in real time, and adjustments can be made accordingly. This vision is within reach, but its realization entirely depends on establishment of databases that allow a quick and robust comparison of the patient's profiles against that of healthy controls and other patients. Thus, we contend that the urinary proteome database presented here is a major step forward in this direction. We anticipate that the availability of such databases in the future will significantly improve the options for patients with respect to diagnosis and therapy.
METHODS
Samples were collected at >20 clinical centers according to established protocols 20, 21 .
Informed consent was obtained from all patients and ethical approval was obtained from the appropriate boards for all samples included.
Sample preparation
All samples for CE-MS analysis were from spontaneously voided urine and were stored at -20°C until analysis. For proteomic analysis, a 0.7 mL aliquot was thawed immediately before use and diluted with 0.7 mL 2 M urea, 10 mM NH 4 OH containing 0.02 % SDS. To remove proteins of higher molecular mass, the sample was filtered with Centricon ultracentrifugation filter devices (30 kDa molecular weight cut-off; Millipore, Billerica, MA, USA) at 3,000 g until 1.1 ml of filtrate was obtained. The filtrate was then applied onto a PD-10 desalting column (Amersham Bioscience, Sweden) equilibrated in 0.01% NH 4 OH in HPLC-grade water to remove urea, electrolytes and salts. Finally, all samples were lyophilized, stored at 4°C, and resuspended in HPLC-grade water shortly before CE-MS analysis, as described 21 . The re-suspension volume was adjusted to 0.8 μg/μL, according to the peptide content of the sample as measured by BCA assay (Interchim, Montlucon, France).
CE-MS analysis
CE-MS analysis was performed with a P/ACE MDQ capillary electrophoresis system (Beckman Coulter, USA) coupled online to a Micro-TOF MS (Bruker Daltonic, Germany) 21 The ESI sprayer (Agilent Technologies, USA) was grounded, and the ion spray interface potential was set between -4.0 and -4. 
CE-FT-ICR-MS analysis
For CE-FT-ICR-MS, a Bruker Daltonic Apex Qe instrument equipped with a 12-T magnet and an Apollo II ion source was used. Coupling of the P/ACE 5510 capillary electrophoresis system (Beckman Coulter, USA) via the Agilent ESI sprayer was performed as above. The instrument was tuned with a peptide standard mix 21 and externally mass calibrated on arginine clusters (< 0.1 ppm calibration errors). Mass spectra were acquired over an m/z range of 300-2,000. Ions were stored in the collision cell for 500 ms and 5 spectra were accumulated for each scan, resulting in a scan rate of 5 s.
Data processing
Mass spectral ion peaks representing identical molecules at different charge states were showed high variability, mostly due to different amounts of salt and peptides in the sample.
Consequently, CE-migration time and ion signal intensity were normalized based on reference signals by 200 abundant "housekeeping" peptides generally present in urine, which serve as internal standards 20, 21 . These "internal standards" were present in at least 90% of all urine samples with a relative standard deviation less than 100%. if the mass deviation was lower than 50 ppm for small peptides or 75 ppm for larger peptides and proteins. The CE migration time deviation was linearly increased over the entire electropherogram from 2-5%. These clustering parameters showed minimal error rates and considered increased peak widths at higher migration times. Disease-specific protein/peptide patterns were generated using support-vector-machine (SVM) based
MosaCluster software 17 .
Statistical analysis
Estimates of sensitivity and specificity were calculated based on tabulating the number of and references therein) available at www.bioconductor.org.
Sequencing of peptides
Candidate biomarkers and other native peptides from urine were sequenced using CE-or LC-MS/MS analysis as recently described in detail 28 .
In addition, MS/MS experiments were performed on an Ultimate 3000 nanoflow system (Dionex/LC Packings, USA) connected to an LTQ Orbitrap hybrid mass spectrometer (Thermo Fisher Scientific, Germany) equipped with a nanoelectrospray ion source. The mass spectrometer was operated in data-dependent mode to automatically switch between MS and MS/MS acquisition. Survey full-scan MS spectra (from m/z 300-2,000) were acquired in the Orbitrap. Ions were sequentially isolated for fragmentation in the linear ion trap using collisionally induced dissociation. General mass spectrometric conditions were: electrospray voltage, 1.6 kV; no sheath and auxiliary gas flow; ion transfer tube temperature, 225°C; collision gas pressure, 1.3 mT; normalized collision energy, 32% for MS 2 . Ion selection threshold was 500 counts for MS/MS.
Samples were also analyzed using Electron Transfer Dissociation (ETD) [43] [44] [45] .
Peptides were separated by nRP-HPLC (Agilent 1100; flow split by tee to~60 nL/min) and introduced into an ETD-capable Finnigan LTQ quadrupole linear ion trap via nESI, using previously described instrumental parameters 46 .
All resulting MS/MS data were submitted to MASCOT (www.matrixscience.com) for a search against human entries in the MDSB Protein Database. Accepted parent ion mass deviation was 50 ppm; accepted fragment ion mass deviation was 500 ppm. Only search results with a MASCOT peptide score of 20 or better, which also met ion coverage stipulations as related to the main spectral features were included. Data files from experiments performed on the ETD-enabled LTQ were searched against the NCBI human non-redundant database using the Open Mass Spectrometry Search Algorithm (OMSSA),
with an e-value cut-off of 0.01. The number of basic and neutral polar amino acids of the peptide sequences was utilized to correlate peptide sequencing data to CE-MS data, as described earlier 28 . 
Supplementary table 2:
352 peptide sequences obtained with MS/MS sequencing.
The table contains (from left to right) the number of the data base entry (Protein ID), the associated mass, the CE migration time, and the amplitude of the peptide signal. The additional information after sequence analysis is the peptide sequence, the name of the protein fragment, the SwissProt entry, the accession number, the calculated monoisotopic mass, and the deviation between observed and expected mass. In addition, FT-ICR masses are shown, including their deviation to the calculated mass. Fig. 4 
